Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Changes in Beneficial Ownership · 4

Assembly Biosciences, Inc.

ASMBNASDAQEQUITYCurrent

Changes in Beneficial Ownership

Filed Jun 5, 2026Accepted Jun 5, 2026, 4:30 PM EDTFiling CIK 1426800Accession 0001193125-26-259697
Share

Structured filing — 4

ownership.xml

Open full document ↗

Filing details

Report period
2026-06-04
Issuer
ASSEMBLY BIOSCIENCES, INC.
Issuer CIK
0001426800
Trading symbol
ASMB

Reporting owner 1

Name
ALTIG ANTHONY E
Reporting owner CIK
0001215907
Relationship
Director
Address
C/O ASSEMBLY BIOSCIENCES, INC., TWO TOWER PLACE, 7TH FLOOR, SOUTH SAN FRANCISCO, CA, 94080

Derivative transactions

Derivative transactions · 1 reported row
SecurityConversion / exercise price (USD)Transaction dateCodeAmountA / DPrice (USD)ExercisableExpiresUnderlying securityUnderlying sharesOwned afterOwnership
Stock Option (right to buy)24.112026-06-04A · Form 48,000A0[F1]2036-06-04Common Stock8,0008,000D
Table key
A · Form 4
Acquisition by grant, award or otherwise under Rule 16b-3(d)
A
Acquired
D
Direct

Footnotes

F1
Grant of stock options. The stock options vest, assuming continuous service, upon the earlier of (1) June 4, 2027 and (2) the date of the Issuer's 2027 annual meeting of stockholders.↩ 1

Signature 1

Signed
/s/ John O. Gunderson, as Attorney-in-Fact
Date
2026-06-05

Company context

In October 2023, Assembly Bio and Gilead entered into a 12-year collaboration to advance the research and development of novel antiviral therapies. Under the collaboration, Gilead has an option to obtain exclusive rights to each of Assembly Bio’s current and future programs, and Assembly Bio is eligible to receive collaboration extension fees, option fees, milestone payments and royalties. Following Gilead’s exercise of an option, Assembly Bio has the right to elect to share costs and profits in the U.S., as well as certain co-promotion rights for future programs.

Current securities

Recent company filings

  1. SCHEDULE 13G/A - filed by Janus Henderson Group Ltd. regarding ASSEMBLY BIOSCIENCES, INC.Nov 16, 2026
  2. 10-Q filingNov 12, 2026
  3. Results of Operations and Financial ConditionNov 12, 2026
  4. S-8 filingAug 20, 2026
  5. Results of Operations and Financial ConditionAug 14, 2026

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.